Work

Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) - Phase 2 Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations: Sub-protocol EAY131-M

Year: 2022

Type: article

Source: European Journal of Cancer

DOI: 10.1016/s0959-8049(22)00870-x

Authors: J. Hays, Z. Song, P. Paik, G. Iyer, E. Mitchell, J. Wright, L. Doyle, R. Gray, V. Wang, L. McShane, L. Rubinstein, D. Patton, M. Williams, S. Hamilton, B. Conley, C. Arteaga, L. Harris, P. O’Dwyer, A. Chen, K. Flaherty

Institutions: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Thomas Jefferson University Hospital, National Cancer Institute, Frederick National Laboratory for Cancer Research, City Of Hope National Medical Center, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Abramson Cancer Center, University of Pennsylvania, Massachusetts General Hospital

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4307909025

FWCI: 0.276

Cites:

Cited by: 4

Related to: 10